We use cookies for a better user experience. Read our Privacy Policy

I Agree

Nasal Polyps Treatment Market

Nasal Polyps Treatment Market (Type of Treatment: Pharmacological Therapies (Corticosteroids, Antibiotics, Leukotriene Inhibitors, Others), and Surgeries (Polypectomy, Functional Endoscopic Sinus Surgery (FESS)); End User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Nasal Polyps Treatment Market: Increasing Efficacy of Treatments through Ongoing Research

The healthcare industry is primarily driven by constant research experiments, and the nasal polyps treatment market is no exception, as it is evolving rapidly with the unique outcomes of these studies to improve the effectiveness of therapies. Extensive studies on nasal polyps are leading to new treatment opportunities for health conditions such as asthma, sinusitis, allergies, and more. These studies are laying the foundation for understanding the causes of developing nasal polyps, and introducing more effective treatments in this landscape.

Recently, NIAID (National Institute of Allergy and Infectious Diseases) initiated a study to understand the causes of, and ultimately develop treatments for nasal polyps. The study found that, exposure of the epithelial cells to Dupilumab, a drug used to treat patients suffering from asthma and allergic inflammation, can influence shifts in gene expression and cell behavior. However, the study also found that, the same impact was not completely observed on several polyp-associated genes, suggesting the need for innovation in nasal polyps treatments that can also be effective on other polyps-related diseases.

Studies have also found that, the prevalence of chronic rhinosinusitis with nasal polyps is increasing, and patients are tied to a high risk of depression and anxiety. This is creating the need for chronic rhinosinusitis treatments as well as medications that can shrink the size of nasal polyps while facilitating the treatment for rhinosinusitis, which is likely to incur transformational changes in the way nasal polyps are treated, in the coming years.

In terms of scope for the nasal polyps treatment market, the growth indicator is projected to show an immense rise in the coming years. The market is currently valued at ~US$ 3.9 billion, and is likely to reach ~US$ 4 billion by 2019 end. An increasing number of ongoing studies is expected to drive the rising tide of innovation in this landscape, and the nasal polyps treatment market is expected to witness impressive growth in the coming decade.

nasal polyps treatment market infographic

Identify the key factors that will drive your company’s growth. Request a brochure of this report here 

Minimally-Invasive Surgical Treatments to Witness High Inclination from Patients

Patients’ preferences, shifting away from invasive treatments to non-invasive treatments, are having a significant impact on the emerging trends in the nasal polyps treatment market. Though the market is predominantly subjugated by pharmacological therapies such as corticosteroids, antibiotics, leukotriene inhibitors, hospitals and specialty clinics are also aiming to offer minimally-invasive surgical treatments that can cure, not only nasal polyps, but also various other health complications caused due to nasal polyps.

Functional endoscopic sinus surgery (FESS)—a minimally-invasive surgical treatment for nasal polyps—is emerging as one of the most favored nasal polyps treatments by patients as well as medical professionals. Its adoption over invasive surgical treatments such as polypectomy surgery of nasal polyps, is mainly attributed to its minimally-invasive nature that allows surgeons to directly visualize the critical areas of the nasal passage, which signifies more comfort and efficiency for both, patients and medical professionals.

Though the rising pervasiveness of asthma, nasal polys, and sinusitis has led to an increase in the efforts for the development of novel, non-invasive therapies, many nasal polyps treatments are challenged by bygone therapies such as systemic or oral corticosteroids and intranasal sprays.  Stakeholders are focusing on their novel therapies and treatments in the pipeline that can prove more effective and efficient than the ones that are already popular in the market. For instance, GlaxoSmithKline – a British multinational pharmaceutical company – announced that the European Commission has approved Nucala (mepolizumab), a targeted monoclonal antibody for the treatment of various health conditions, and is in the pipeline for further investigation for the treatment of nasal polyposis.

nasal polyps treatment market segmentation

Want to know more such detailed insights of “Nasal Polyps Treatment Market”? Request a PDF sample here?

High Cost of Treatment and Post-surgical Complications Negatively Impact Market Growth

Although the number of stakeholders entering the nasal polyps treatment market is increasing rapidly, resistances such as inefficacy of pharmacological therapies, high cost of treatment, and complications associated with sinus surgeries are expected to slow down the growth of the nasal polyps treatment market in the coming years. These restraints are a result of common fears pertaining to steroid therapy, and the high risk of side effects such as weight gain, loss of bone mineral density, and cataract formation in the eyes.

In addition, some of the complications subject to sinus surgeries are excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation. Also the expensive procedure associated with functional endoscopic sinus surgery (FESS) as compared to other low-cost alternatives such as courses of intranasal sprays, and the recurrence of diseases post-surgery, are hindering the growth prospects of surgical treatments in the global nasal polyps treatment market.

However, key competitors are strategically tackling these issues by broadening their product portfolios for nasal polyps therapies, and introducing innovative treatments that are cost-efficient as well as more effective, to secure their position as leading players in the nasal polyps treatment market. For example, in September 2018, Novartis International AG – a leading a Swiss multinational pharmaceutical company – announced that it has received an approval from the U.S Food and Drug Administration (FDA) for 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes (PFS), which are used as an add-on formulation for both, chronic idiopathic urticaria (CIU) and allergic asthma indications with its new product – Xolair (Omalizumab).

Expanding operations in future? To get the perfect launch ask for a custom report here

Analysts’ View of the Nasal Polyps Treatment Market

Authors of this report anticipate a favorable growth landscape for the nasal polyps treatment market over the forecast period of 2019–2027. The market is projected to expand its boundaries in North America, Asia Pacific, and Europe, with ongoing research directed towards introducing efficient treatments for nasal polyps, as well as other respiratory diseases triggered by the condition. The adoption of minimally-invasive surgical treatments is expected to increase among healthcare organizations; ambulatory surgical centers are projected to headline the winning race in the competitive landscape.

Functional endoscopic sinus surgery (FESS) and other less-invasive surgeries are gaining traction among consumers as well as manufacturers. However common fears and stigma attached to steroid therapies, low-cost alternatives, short-term solutions, and recurrence of diseases post-surgery are some of the hindrances that are affecting the nasal polyps treatment market.

To deal with these challenges, market players must focus on prioritizing investments toward research & development to diversify their range of nasal polyps treatments. In addition, improving awareness about the efficacy of their products among end users will become inevitable, and collaborating with key players to co-promote novel treatments will help them improve their sales performance in this landscape.

Global Nasal Polyps Treatment Market: Overview

  • The global nasal polyps treatment market was valued at ~US$ 3.9 Bn in 2018, and is projected to reach ~US$ 6 Bn by 2027, expanding at a CAGR of ~5% from 2019 to 2027.
  • The global nasal polyps treatment market is driven primarily by the rise in the prevalence of chronic rhinosinusitis with nasal polyps across the globe.
  • Nasal polyps are soft, painless, fleshy swellings or non-cancerous growths in the paranasal sinuses and lining in the nasal passages due to chronic inflammation of the mucosa.
  • Nasal congestion or obstruction, sinofacial pain and pressure, loss of sense of smell, and rhinorrhea are the major symptoms associated with nasal polyps.
  • Pharmacological therapies such as corticosteroids, antibiotics, leukotriene inhibitors, and antihistamines, and surgical procedures such as functional endoscopic sinus surgery and polypectomy are the major options for nasal polyps treatment.

Global Nasal Polyps Treatment Market: Drivers & Restraints

  • The global nasal polyps treatment market is growing at a rapid pace, owing to an increase in the population diagnosed with nasal polyps, rise in the prevalence of co-morbidities such as asthma, surge in the demand for minimally-invasive surgeries, and rich pipeline of nasal polyps treatment options.
  • Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly common condition affecting the population aged 30 years and above. The disease is more common in men than women. It is estimated that nasal polyps is prevalent in 1% to 4% of the general population across the globe.
  • However, high cost and complications associated with sinus surgical procedures, including cerebrospinal fluid leak, excessive bleeding, visual disturbances, postoperative scarring, inflammation, and recurrence of nasal polyps are anticipated to hamper the global nasal polyps treatment market during the forecast period.

Global Nasal Polyps Treatment Market: Market Segmentation

  • The global nasal polyps treatment market has been segmented based on type of treatment, end user, and region. In terms of type of treatment, the global nasal polyps treatment market has been categorized into pharmacological therapies and surgeries.
  • The pharmacological therapies segment dominated the global nasal polyps treatment market in 2018, and is projected to grow at a rapid pace during the forecast period.
  • Pharmacological therapies have been classified into corticosteroids, antibiotics, leukotriene inhibitors, and others. The corticosteroids sub-segment is expected to expand at a significant CAGR during the forecast period, owing to an increase in the demand for topical corticosteroids in the form of intranasal sprays and drops.
  • Topical corticosteroids induce a non-specific anti-inflammatory response that helps reduce or shrink the size of nasal polyps, and thereby help relieve the symptoms of nasal polyps in patients. Nasonex (mometasone) and Xhance (fluticasone propionate) are the major corticosteroid brands available in the market.
  • Based on end user, the global nasal polyps treatment market has been segmented into ambulatory surgical centers, hospitals, and specialty clinics.
  • The hospitals segment is anticipated to account for a significant share of the global nasal polyps treatment market during the forecast period. Growth of the segment can be attributed to the rise in the demand for sinus surgeries for the removal of nasal polyps, leading to increased hospitalization and wide range of services offered by hospitals at a single site.

Global Nasal Polyps Treatment Market: Regional Segmentation

  • Geographically, the global nasal polyps treatment market has been categorized into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa
  • North America
    • North America accounted for a prominent share of the global nasal polyps treatment market in 2018. It is anticipated to continue to dominate the global nasal polyps treatment market during the forecast period. The presence of a large target population that is affected by chronic rhinosinusitis with nasal polyps and increasing sinus surgeries performed in the U.S. are the major factors attributed to the region’s dominance.
    • According to the Centers for Disease Control and Prevention (CDC), nearly 30 million adults are affected with chronic sinusitis in the U.S. Of these, 25% to 30% patients, i.e., 10 million adults, have nasal polyposis.
  • Europe
    • The nasal polyps treatment market in Europe is anticipated to expand at a considerable CAGR from 2019 to 2027, owing to the presence of a large geriatric population, high prevalence of osteoarthritis, increase in the number of nasal polyps treatment surgeries, and well-established market players in the region.
    • The nasal polyps treatment market in the U.K. is likely to grow at a rapid pace during the forecast period, owing to the high prevalence of chronic rhinosinusitis (CRS), which is a highly prevalent condition affecting 10% of the adult population of the country.
    • According to the National Institute for Health Sciences (NHS), there were 18,409 admissions for chronic sinusitis and nasal polyps in England in 2015.
  • Asia Pacific
    • The nasal polyps treatment market in Asia Pacific is likely to expand at a significant CAGR from 2019 to 2027. The presence of a large patient pool with inflammatory and respiratory disorders in developing countries such as India and China, and increase in sinus surgeries performed in developed countries in the region, are anticipated to propel the nasal polyps treatment market.

Global Nasal Polyps Treatment Market: Major Players

Key players operating in the global nasal polyps treatment market include

  • Sanofi
  • Merck & Co, Inc.
  • OptiNose US, Inc.
  • Intersect ENT, Inc.
  • Pfizer
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd

​These companies have diverse portfolios of nasal polyps treatments along with a strong presence across the globe.

  • Industry players focus on research and development activities along with strategic collaborations & partnerships for new product launches in order to expand their product portfolio and strengthen their position in the global  nasal polyps treatment market.
  • For instance, in September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE, a fluticasone propionate corticosteroid nasal spray manufactured by OptiNose US, Inc. This nasal spray helps administer medication deep inside the nose, leading to the effective treatment of nasal polyps in patients aged 18 and above.

Segmentation of the Nasal Polyps Treatment Market

TMR’s study on the nasal polyps treatment market includes information bifurcated into three sections - by type of treatment, by end user, and by region. Changing industry trends and other crucial market dynamics associated with these sections of the nasal polyps treatment market are discussed in detail.

Type of Treatment

Pharmacological Therapies

  • Corticosteroids
  • Antibiotics
  • Leukotriene Inhibitors
  • Others

Surgeries

  • Polypectomy
  • Functional Endoscopic Sinus Surgery (FESS)

End User

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of nasal polyps treatment market?

Nasal polyps treatment market to reach a value of ~ US$ 6 Bn by 2027

What is the anticipated CAGR of the nasal polyps treatment market in the forecast period?

Nasal polyps treatment market is projected to expand at a CAGR of ~5% from 2019 to 2027

What are the key driving factors for the growth of the nasal polyps treatment market?

Nasal polyps treatment market is driven by rise in prevalence of CRSwNP across the globe

Which region is expected to project the highest market share in the global nasal polyps treatment market?

The pharmacological therapies segment dominated the global nasal polyps treatment market, and the trend is projected to continue during the forecast period

Who are the key players in the nasal polyps treatment market?

Key players in the global nasal polyps treatment market include are Merck & Co, Inc., Intersect ENT, Inc., OptiNose US, Inc., Sanofi, Pfizer, GlaxoSmithKline plc

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nasal Polyps Treatment Market
4. Market Overview

    4.1. Introduction
        4.1.1. Treatment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Nasal Polyps Treatment Market Analysis and Forecast, 2017–2027
        4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
    5.1. Key Industry Developments
    5.2. Pipeline Analysis
    5.3. Qualitative Assessment on Novel Treatment Options for Nasal Polyps: Biologics & Stents
        5.3.1. Key Insights on Biologics (Xolair, Dupixent, Nucala) 
6. Global Nasal Polyps Treatment Market Analysis and Forecast, by Type of Treatment 
    6.1. Introduction & Definition
    6.2. Market Value Forecast, by Type of Treatment , 2017–2027
        6.2.1. Pharmacological Therapies
            6.2.1.1. Corticosteroids 
            6.2.1.2. Antibiotics 
            6.2.1.3. Leukotriene Inhibitors 
            6.2.1.4. Others
        6.2.2. Surgeries
            6.2.2.1. Polypectomy 
            6.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    6.3. Market Attractiveness By Type of Treatment 
7. Global Nasal Polyps Treatment Market Analysis and Forecast, by End-user 
    7.1. Introduction & Definition
    7.2. Market Value Forecast, by End-user, 2017–2027
        7.2.1. Hospitals 
        7.2.2. Ambulatory Surgical Centers 
        7.2.3. Specialty Clinics 
    7.3. Market Attractiveness, by End-user 
8. Global Nasal Polyps Treatment Market Analysis and Forecast, by Region
    8.1. Introduction
    8.2. Market Value Forecast, by Region
        8.2.1. North America 
        8.2.2. Europe 
        8.2.3. Asia Pacific 
        8.2.4. Latin America 
        8.2.5. Middle East & Africa 
    8.3. Market Attractiveness, by Country/Region
9. North America Nasal Polyps Treatment Market Analysis and Forecast
    9.1. Introduction
    9.2. Market Value Forecast, by Type of Treatment , 2017–2027
        9.2.1. Pharmacological Therapies
            9.2.1.1. Corticosteroids 
            9.2.1.2. Antibiotics 
            9.2.1.3. Leukotriene Inhibitors 
            9.2.1.4. Others
        9.2.2. Surgeries
            9.2.2.1. Polypectomy 
            9.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    9.3. Market Value Forecast, by End-user, 2017–2027
        9.3.1. Hospitals 
        9.3.2. Ambulatory Surgical Centers 
        9.3.3. Specialty Clinics 
    9.4. Market Value Forecast, by Country, 2017–2027
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis 
        9.5.1. By Type of Treatment 
        9.5.2. By End-user 
        9.5.3. By Country
10. Europe Nasal Polyps Treatment Market Analysis and Forecast
    10.1. Introduction
    10.2. Market Value Forecast, by Type of Treatment , 2017–2027
        10.2.1. Pharmacological Therapies
            10.2.1.1. Corticosteroids 
            10.2.1.2. Antibiotics 
            10.2.1.3. Leukotriene Inhibitors 
            10.2.1.4. Others
        10.2.2. Surgeries
            10.2.2.1. Polypectomy 
            10.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    10.3. Market Value Forecast, by End-user, 2017–2027
        10.3.1. Hospitals 
        10.3.2. Ambulatory Surgical Centers 
        10.3.3. Specialty Clinics 
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Spain
        10.4.5. Italy
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis 
        10.5.1. By Type of Treatment 
        10.5.2. By End-user 
        10.5.3. By Country/Sub-region
11. Asia Pacific Nasal Polyps Treatment Market Analysis and Forecast
    11.1. Introduction
    11.2. Market Value Forecast, by Type of Treatment, 2017–2027
        11.2.1. Pharmacological Therapies
            11.2.1.1. Corticosteroids 
            11.2.1.2. Antibiotics 
            11.2.1.3. Leukotriene Inhibitors 
            11.2.1.4. Others
        11.2.2. Surgeries
            11.2.2.1. Polypectomy 
            11.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    11.3. Market Value Forecast, by End-user, 2017–2027
        11.3.1. Hospitals 
        11.3.2. Ambulatory Surgical Centers 
        11.3.3. Specialty Clinics 
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis 
        11.5.1. By Type of Treatment 
        11.5.2. By End-user 
        11.5.3. By Country/Sub-region
12. Latin America Nasal Polyps Treatment Market Analysis and Forecast
    12.1. Introduction
    12.2. Market Value Forecast, by Type of Treatment, 2017–2027
        12.2.1. Pharmacological Therapies
            12.2.1.1. Corticosteroids 
            12.2.1.2. Antibiotics 
            12.2.1.3. Leukotriene Inhibitors 
            12.2.1.4. Others
        12.2.2. Surgeries
            12.2.2.1. Polypectomy 
            12.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    12.3. Market Value Forecast, by End-user, 2017–2027
        12.3.1. Hospitals 
        12.3.2. Ambulatory Surgical Centers 
        12.3.3. Specialty Clinics 
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis 
        12.5.1. By Type of Treatment 
        12.5.2. By End-user 
        12.5.3. By Country/Sub-region
13. Middle East & Africa Nasal Polyps Treatment Market Analysis and Forecast
    13.1. Introduction
    13.2. Market Value Forecast, by Type of Treatment , 2017–2027
        13.2.1. Pharmacological Therapies
            13.2.1.1. Corticosteroids 
            13.2.1.2. Antibiotics 
            13.2.1.3. Leukotriene Inhibitors 
            13.2.1.4. Others
        13.2.2. Surgery 
            13.2.2.1. Polypectomy 
            13.2.2.2. Functional Endoscopic Sinus Surgery (FESS) 
    13.3. Market Value Forecast, by End-user, 2017–2027
        13.3.1. Hospitals 
        13.3.2. Ambulatory Surgical Centers 
        13.3.3. Specialty Clinics 
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis 
        13.5.1. By Type of Treatment 
        13.5.2. By End-user 
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player - Competition Matrix (By Tier and Size of companies)
    14.2. Global Nasal Polyps Treatment Market Position Analysis, by Company, 2018
    14.3. Company Profiles
        14.3.1. OptiNose US, Inc.
        14.3.2. Regeneron Pharmaceuticals, Inc.
        14.3.3. Merck & Co., Inc.
        14.3.4. Pfizer, Inc.
        14.3.5. F. Hoffmann La-Roche, Ltd. 
        14.3.6. Intersect ENT, Inc.
        14.3.7. GlaxoSmithKline plc 
        14.3.8. Sanofi
        14.3.9. Novartis AG

List of Tables

Table 01: Pipeline Analysis: Nasal Polyps
Table 02: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 03: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 04: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 05: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 06: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 08: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 09: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 10: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 11: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 12: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 14: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 15: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 16: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 17: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 19: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 20: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 21: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 22: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 24: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 25: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 26: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 27: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 28: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 29: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 30: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 31: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027

List of Figures

Figure 01: Global Nasal Polyps Treatment Market Snapshot
Figure 02: Global Nasal Polyps Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027
Figure 03: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 04: Global Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018
Figure 05: Global Nasal Polyps Treatment Market Value Share (%), by End-user, 2018
Figure 06: Global Nasal Polyps Treatment Market Value Share (%), by Region, 2018
Figure 07: Nasal Polyps Treatment Market - Collaborations, Partnerships & New Product Launch 
Figure 08: Global Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 09: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacological Therapies, 2017–2027
Figure 10: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgeries, 2017–2027
Figure 11: Global Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 12: Global Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 13: Global Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 14: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 15: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Surgical Centers, 2017–2027
Figure 16: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027
Figure 17: Global Nasal Polyps Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 18: Global Nasal Polyps Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 19: North America Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 20: North America Nasal Polyps Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 21: North America Nasal Polyps Treatment Market Attractiveness Analysis, by Country, 2019–2027
Figure 22: North America Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 23: North America Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 24: North America Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 25: North America Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 26: Europe Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 27: Europe Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: Europe Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 29: Europe Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 30: Europe Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 31: Europe Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 32: Europe Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 33: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 34: Asia Pacific Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 35: Asia Pacific Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 36: Asia Pacific Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 37: Asia Pacific Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 38: Asia Pacific Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 39: Asia Pacific Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 40: Latin America Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 41: Latin America Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 42: Latin America Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 43: Latin America Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 44: Latin America Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 45: Latin America Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 46: Latin America Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 47: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 48: Middle East & Africa Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 49: Middle East & Africa Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 50: Middle East & Africa Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 51: Middle East & Africa Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 52: Middle East & Africa Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 53: Middle East & Africa Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 54: Global Nasal Polyps Treatment Market Position Analysis, by Top Company Ranking, 2018
Figure 55: OptiNose US, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 56: OptiNose US, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 57: Regeneron Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 58: Regeneron Pharmaceuticals, Inc. R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 59: Regeneron Pharmaceuticals Inc., Breakdown of Net Sales (%), by Product, 2018
Figure 60: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 61: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 62: Merck & Co., Inc., Breakdown of Net Sales (%), by Region, 2018
Figure 63: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 64: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 65: Pfizer, Inc., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 66: Pfizer, Inc., Breakdown of Net Sales (%), by Region, 2018
Figure 67: Pfizer, Inc., R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 68: F. Hoffmann-La Roche, Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 69: F. Hoffmann-La Roche, Ltd., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 70: F. Hoffmann-La Roche, Ltd., Breakdown of Net Sales (%), by Region, 2018
Figure 71: F. Hoffmann-La Roche, Ltd., R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 72: Intersect ENT, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 73: Intersect ENT, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 74: GlaxoSmithKline plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 75: GlaxoSmithKline plc, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 76: GlaxoSmithKline plc, Breakdown of Net Sales (%), by Geography, 2018
Figure 77: GlaxoSmithKline plc, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 78: Sanofi, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 79: Sanofi, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 80: Sanofi, Breakdown of Net Sales (%), by Geography, 2018
Figure 81: Sanofi, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 82: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 83: Novartis AG, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 84: Novartis AG, Breakdown of Net Sales (%), by Region, 2018
Figure 85: Novartis AG, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved